These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107. Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse. Cohen OC; Counsell N; Rabin N; Popat R; Owen RG; Popova B; Schofield O; Clifton-Hadley L; Lyons-Lewis J; Rawstron A; Spence C; de Tute RM; Hughes D; Moore S; Smith P; Yong KL Br J Haematol; 2019 Jun; 185(5):948-951. PubMed ID: 30460696 [No Abstract] [Full Text] [Related]
108. Autologous graft versus myeloma: it's not a myth. Dong S; Ghobrial IM J Clin Invest; 2019 Jan; 129(1):48-50. PubMed ID: 30457981 [TBL] [Abstract][Full Text] [Related]
109. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Ravi P; Kumar SK; Roeker L; Gonsalves W; Buadi F; Lacy MQ; Go RS; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV Blood Cancer J; 2018 Nov; 8(12):116. PubMed ID: 30442928 [TBL] [Abstract][Full Text] [Related]
110. Venetoclax for the treatment of multiple myeloma. Vaxman I; Sidiqi MH; Gertz M Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277 [No Abstract] [Full Text] [Related]
111. Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial. Lee DJ; O'Donnell EK; Raje N; Panaroni C; Redd R; Ligibel J; Sears DD; Nadeem O; Ghobrial IM; Marinac CR JMIR Res Protoc; 2024 Mar; 13():e51368. PubMed ID: 38466984 [TBL] [Abstract][Full Text] [Related]
112. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552 [TBL] [Abstract][Full Text] [Related]
113. State of the science in smoldering myeloma: Should we be treating in the clinic? Hill E; Dew A; Kazandjian D Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611 [TBL] [Abstract][Full Text] [Related]
114. Risk Stratification and Treatment in Smoldering Multiple Myeloma. Lussier T; Schoebe N; Mai S Cells; 2021 Dec; 11(1):. PubMed ID: 35011692 [TBL] [Abstract][Full Text] [Related]
115. Timing of treatment of smoldering myeloma: delay until progression. Kumar SK Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069 [TBL] [Abstract][Full Text] [Related]
116. Timing of treatment of smoldering myeloma: early treatment. Mateos MV; González-Calle V Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068 [TBL] [Abstract][Full Text] [Related]
117. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950 [TBL] [Abstract][Full Text] [Related]